We postulate that if FGF23’s actions on cardiac myocytes are reversible, the pharmacological blockade of FGF23/FGFR4 signaling might attenuate LVH and prevent the progression of cardiac injury in CKD. The gene discussed is FGFR4; the disease is chronic kidney disease.